[
  {
    "ts": null,
    "headline": "Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health",
    "summary": "We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Viatris, Inc. stands second among them. Viatris, Inc. (NASDAQ:VTRS) reported strong Q2 2025 results, generating approximately $79 million in revenue from new products while reaffirming its full-year financial guidance. The company continues to advance its pharmaceutical pipeline, with a focus on […]",
    "url": "https://finnhub.io/api/news?id=3233feb6e63e25d161e947565aac390dc210598ebcd8869fe65ddace4e359384",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756458207,
      "headline": "Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health",
      "id": 136569896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Viatris, Inc. stands second among them. Viatris, Inc. (NASDAQ:VTRS) reported strong Q2 2025 results, generating approximately $79 million in revenue from new products while reaffirming its full-year financial guidance. The company continues to advance its pharmaceutical pipeline, with a focus on […]",
      "url": "https://finnhub.io/api/news?id=3233feb6e63e25d161e947565aac390dc210598ebcd8869fe65ddace4e359384"
    }
  }
]